27593936|t|TFAP2C promotes lung tumorigenesis and aggressiveness through miR-183 - and miR-33a -mediated cell cycle regulation
27593936|a|Non-small cell lung cancer (NSCLC) remains one of the leading causes of death worldwide, and thus new molecular targets need to be identified to improve treatment efficacy. Although epidermal growth factor receptor (EGFR)/ KRAS mutation -driven lung tumorigenesis is well understood, the mechanism of EGFR / KRAS -independent signal activation remains elusive. Enhanced TFAP2C (transcription factor activating enhancer-binding protein 2C) expression is associated with poor prognosis in some types of cancer patients, but little is known of its relation with the pathogenesis of lung cancer. In the present study, we found that TFAP2C overexpression was associated with cell cycle activation and NSCLC cell tumorigenesis. Interestingly, TFAP2C blocked AKAP12 -mediated cyclin D1 inhibition by inducing the overexpression of oncogenic microRNA (miRNA)-183 and simultaneously activated cyclin-dependent kinase 6 -mediated cell cycle progression by downregulating tumor-suppressive miRNA-33a. In a mouse xenograft model, TFAP2C promoted lung tumorigenesis and disease aggressiveness via the miR-183 and miR-33a pathways. The study provides a mechanism of mitogenic and oncogenic signaling via two functionally opposed miRNAs and suggests that TFAP2C -induced cell cycle hyperactivation contributes to lung tumorigenesis.
27593936	0	6	TFAP2C	T116,T123	C1529556
27593936	16	20	lung	T023	C0024109
27593936	21	34	tumorigenesis	T191	C0596263
27593936	39	53	aggressiveness	T191	C2945759
27593936	62	69	miR-183	T114,T123	C1101610
27593936	76	83	miR-33a	T114,T123	C1101610
27593936	94	115	cell cycle regulation	T043	C1155872
27593936	116	142	Non-small cell lung cancer	T191	C0007131
27593936	144	149	NSCLC	T191	C0007131
27593936	188	193	death	T040	C0011065
27593936	194	203	worldwide	T098	C2700280
27593936	218	235	molecular targets	T104,T120	C1513403
27593936	269	287	treatment efficacy	T080	C0087113
27593936	298	330	epidermal growth factor receptor	T116,T126,T192	C0034802
27593936	332	336	EGFR	T028	C1414313
27593936	339	343	KRAS	T028	C1537502
27593936	344	352	mutation	T045	C0596611
27593936	361	365	lung	T023	C0024109
27593936	366	379	tumorigenesis	T191	C0596263
27593936	404	413	mechanism	T044	C0678659
27593936	417	421	EGFR	T116,T126,T192	C0034802
27593936	424	428	KRAS	T116,T123	C0763464
27593936	442	459	signal activation	UnknownType	C0678666
27593936	477	492	Enhanced TFAP2C	T116,T123	C1529556
27593936	494	553	transcription factor activating enhancer-binding protein 2C	T116,T123	C1529556
27593936	555	565	expression	T045	C1171362
27593936	569	584	associated with	T080	C0332281
27593936	590	599	prognosis	T201	C3854082
27593936	617	632	cancer patients	T101	C1516213
27593936	679	691	pathogenesis	T046	C0699748
27593936	695	706	lung cancer	T191	C0684249
27593936	723	728	study	T062	C2603343
27593936	744	750	TFAP2C	T116,T123	C1529556
27593936	751	765	overexpression	T045	C1514559
27593936	770	785	associated with	T080	C0332281
27593936	786	807	cell cycle activation	T043	C0007613
27593936	812	817	NSCLC	T191	C0007131
27593936	818	822	cell	T025	C0007634
27593936	823	836	tumorigenesis	T191	C0596263
27593936	853	859	TFAP2C	T116,T123	C1529556
27593936	860	867	blocked	T169	C0332206
27593936	868	874	AKAP12	T116,T123	C1454561
27593936	885	894	cyclin D1	T116,T123	C0174680
27593936	895	905	inhibition	T052	C3463820
27593936	922	936	overexpression	T045	C0017262
27593936	940	958	oncogenic microRNA	T028	C2825314
27593936	959	970	(miRNA)-183	T028	C1537817
27593936	1000	1025	cyclin-dependent kinase 6	T116,T126	C0252132
27593936	1036	1058	cell cycle progression	T043	C1516334
27593936	1062	1076	downregulating	T044	C0013081
27593936	1095	1104	miRNA-33a	T114,T123	C1101610
27593936	1111	1132	mouse xenograft model	T050	C2986594
27593936	1134	1140	TFAP2C	T116,T123	C3712863
27593936	1150	1154	lung	T023	C0024109
27593936	1155	1168	tumorigenesis	T191	C0596263
27593936	1173	1195	disease aggressiveness	T191	C2945759
27593936	1204	1211	miR-183	T114,T123	C1101610
27593936	1216	1223	miR-33a	T114,T123	C1101610
27593936	1224	1232	pathways	T044	C0037080
27593936	1238	1243	study	T062	C2603343
27593936	1255	1264	mechanism	T044	C0678659
27593936	1268	1277	mitogenic	T038	C3537152
27593936	1282	1301	oncogenic signaling	T038	C3537152
27593936	1356	1362	TFAP2C	T116,T123	C1529556
27593936	1372	1398	cell cycle hyperactivation	T043	C0007613
27593936	1414	1418	lung	T023	C0024109
27593936	1419	1432	tumorigenesis	T191	C0596263